Lexeo to acquire Mantle Therapeutics; adds strategic collaborations
LXEO - Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia
Story updates
11:00:24 AM UTC
SquawkNews
LXEO - Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia
11:01:31 AM UTC
SquawkNews
Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia
11:01:39 AM UTC
SquawkNews
Lexeo Therapeutics to Acquire Mantle Therapeutics for Upfront Payment $8.3M >LXEO
11:03:36 AM UTC
SquawkNews
Lexeo signed a definitive deal to acquire Mantle Therapeutics for $8.3M upfront plus up to $13.0M in milestones, expanding FA programs, and announced new CNS collaborations. LXEO affirmed cash runway into 2028 and LX2006 topline data on track for 2H 2027.Material DetailsContext by AI AnalystThis ex…
11:13:58 AM UTC
SquawkNews
Lexeo Therapeutics entered into an Agreement and Plan of Merger to acquire Mantle Therapeutics, adding Mantle as a wholly owned subsidiary. The deal provides $5.3 million in cash and $3.0 million in Lexeo common stock at closing, with potential contingent consideration of up to $13 million, includi…